Kiniksa Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Net Income	14.08	183.36	-157.92	-161.38	-161.87	Upgrade
Depreciation & Amortization	5.4	5.44	4.99	3.81	3.28	Upgrade
Share-Based Compensation	27.15	25.12	25.17	20.88	15.08	Upgrade
Other Operating Activities	-33.33	-208.12	1.47	0.17	-14.86	Upgrade
Operating Cash Flow	13.3	5.81	-126.3	-136.53	-158.37	Upgrade
Operating Cash Flow Growth	129.05%	-	-	-	-	Upgrade
Capital Expenditures	-0.13	-0.01	-0.42	-0.28	-3.2	Upgrade
Change in Investments	-29.43	-8.06	149.05	-23.16	52.42	Upgrade
Other Investing Activities	-	-	-20	-	-	Upgrade
Investing Cash Flow	-29.56	-8.08	128.64	-23.44	49.21	Upgrade
Share Issuance / Repurchase	1.5	2.52	5.89	228.22	84.23	Upgrade
Other Financing Activities	-	-	-	-1.14	-0.12	Upgrade
Financing Cash Flow	1.5	2.52	5.89	227.09	84.11	Upgrade
Net Cash Flow	-14.76	0.25	8.22	67.11	-25.05	Upgrade
Free Cash Flow	13.17	5.79	-126.71	-136.82	-161.57	Upgrade
Free Cash Flow Growth	127.36%	-	-	-	-	Upgrade
Free Cash Flow Margin	4.87%	2.63%	-328.75%	-	-	Upgrade
Free Cash Flow Per Share	0.19	0.08	-1.85	-2.21	-2.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).